{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.08","statisticalMethod":"Wilcoxon rank sum test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.73","value":"4.05"},{"groupId":"OG001","spread":"0.97","value":"6.93"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"description":"Pharmacokinetic parameter Kep was measured by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).","dispersionType":"Standard Error","groups":[{"description":"MGUS (Monoclonal gammopathy of undetermined significance) is a premalignant plasma cell proliferative disorder.","id":"OG000","title":"MGUS (Monoclonal Gammopathy of Undetermined Significance)"},{"description":"Smoldering multiple myeloma (SMM)is a premalignant plasma cell proliferative disorder. Multiple myeloma is a plasma cell neoplasm.","id":"OG001","title":"SMM (Smoldering Multiple Myeloma)/MM (Multiple Myeloma)"}],"paramType":"MEAN","populationDescription":"Serum was not available for three patients in the SMM group.","reportingStatus":"POSTED","timeFrame":"60 days","title":"Comparison of Serum Angiogenic Marker Reverse Contrast Transfer Rate (Kep) Between MGUS and SMM/MM Groups","type":"SECONDARY","unitOfMeasure":"per min"}